# John R. Teerlink

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/john-r-teerlink/

## Facts

| Field | Value |
| --- | --- |
| Citations | 31,883 |
| Field | Heart Failure Treatment and Management |
| h-index | 89 |
| i10-index | 300 |
| Last Known Institution | San Francisco VA Medical Center |
| OpenAlex ID | https://openalex.org/A5017097200 |
| ORCID iD | 0000-0001-9527-0852 |
| Works | 501 |

## Researcher papers

Showing 12 of 21.

- [Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure](https://scholariq.org/papers/universal-definition-and-classification-of-heart-failure-a-report-of-the-heart/)
- [Effect of Nesiritide in Patients with Acute Decompensated Heart Failure](https://scholariq.org/papers/effect-of-nesiritide-in-patients-with-acute-decompensated-heart-failure/)
- [Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure](https://scholariq.org/papers/ultrafiltration-versus-intravenous-diuretics-for-patients-hospitalized-for-acute/)
- [The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial](https://scholariq.org/papers/the-sglt2-inhibitor-empagliflozin-in-patients-hospitalized-for-acute-heart/)
- [Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial](https://scholariq.org/papers/serelaxin-recombinant-human-relaxin-2-for-treatment-of-acute-heart-failure-relax/)
- [2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials](https://scholariq.org/papers/2017-cardiovascular-and-stroke-endpoint-definitions-for-clinical-trials/)
- [Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America](https://scholariq.org/papers/heart-failure-epidemiology-and-outcomes-statistics-a-report-of-the-heart-failure/)
- [Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure](https://scholariq.org/papers/angiotensin-receptor-neprilysin-inhibition-compared-with-enalapril-on-the-risk/)
- [Heart failure](https://scholariq.org/papers/heart-failure/)
- [Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure](https://scholariq.org/papers/cardiac-myosin-activation-with-omecamtiv-mecarbil-in-systolic-heart-failure/)
- [Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm](https://scholariq.org/papers/warfarin-and-aspirin-in-patients-with-heart-failure-and-sinus-rhythm/)
- [Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction](https://scholariq.org/papers/effect-of-empagliflozin-on-the-clinical-stability-of-patients-with-heart-failure/)

## Researcher topics

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Cardiac pacing and defibrillation studies](https://scholariq.org/topics/cardiac-pacing-and-defibrillation-studies/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cardiac Fibrosis and Remodeling](https://scholariq.org/topics/cardiac-fibrosis-and-remodeling/)

## Researcher university

- [San Francisco VA Medical Center](https://scholariq.org/institutions/san-francisco-va-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.